Suppr超能文献

导管原位癌:危险因素及筛查的影响

Ductal carcinoma in situ: risk factors and impact of screening.

作者信息

Virnig Beth A, Wang Shi-Yi, Shamilyan Tatyana, Kane Robert L, Tuttle Todd M

机构信息

Division of Health Policy and Management, School of Public Health, University of Minnesota, A365 Mayo (MMC 729), 420 Delaware St SE, Minneapolis, MN 55455, USA.

出版信息

J Natl Cancer Inst Monogr. 2010;2010(41):113-6. doi: 10.1093/jncimonographs/lgq024.

Abstract

BACKGROUND

The National Institutes of Health Office of Medical Applications of Research commissioned a structured literature review on the incidence of ductal carcinoma in situ (DCIS) as a background paper for the State of the Science Conference on Diagnosis and Management of DCIS.

METHODS

Published studies were abstracted from MEDLINE and other sources. We include articles published through January 31, 2009; 92 publications were abstracted.

RESULTS

DCIS incidence rose from 1.87 per 100,000 in 1973-1975 to 32.5 per 100,000 in 2005. Increases in incidence were greatest in tumors without comedo necrosis. Incidence increased in all ages but more in women older than 50 years. Increased use of mammography explains some but not all of the increased incidence. Risk factors for incident DCIS include older age and positive family history. Whereas tamoxifen prevents both invasive breast cancer and DCIS, raloxifene is associated with decreased invasive breast cancer but not decreased DCIS.

CONCLUSIONS

Scientific questions deserving further investigation include the relationship between mammography use and DCIS incidence and the role of chemoprevention for reducing the incidence of DCIS and invasive breast cancer.

摘要

背景

美国国立卫生研究院医学应用研究办公室委托进行了一项关于导管原位癌(DCIS)发病率的结构化文献综述,作为DCIS诊断与管理科学现状会议的背景文件。

方法

从MEDLINE及其他来源提取已发表的研究。纳入截至2009年1月31日发表的文章;共提取了92篇出版物。

结果

DCIS发病率从1973 - 1975年的每10万人1.87例升至2005年的每10万人32.5例。无粉刺样坏死的肿瘤发病率增长最为显著。各年龄段发病率均有所上升,但50岁以上女性上升幅度更大。乳腺钼靶检查使用增加可解释部分而非全部发病率上升情况。新发DCIS的风险因素包括年龄较大和家族史阳性。他莫昔芬可预防浸润性乳腺癌和DCIS,而雷洛昔芬与浸润性乳腺癌发病率降低相关,但与DCIS发病率降低无关。

结论

值得进一步研究的科学问题包括乳腺钼靶检查使用与DCIS发病率之间的关系,以及化学预防在降低DCIS和浸润性乳腺癌发病率方面的作用。

相似文献

1
Ductal carcinoma in situ: risk factors and impact of screening.
J Natl Cancer Inst Monogr. 2010;2010(41):113-6. doi: 10.1093/jncimonographs/lgq024.
2
Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.
J Natl Cancer Inst. 2010 Feb 3;102(3):170-8. doi: 10.1093/jnci/djp482. Epub 2010 Jan 13.
3
Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
J Natl Cancer Inst Monogr. 2010;2010(41):181-6. doi: 10.1093/jncimonographs/lgq041.
4
Epidemiology of ductal carcinoma in situ.
J Natl Cancer Inst Monogr. 2010;2010(41):139-41. doi: 10.1093/jncimonographs/lgq027.
6
Detection of ductal carcinoma in situ in women undergoing screening mammography.
J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54. doi: 10.1093/jnci/94.20.1546.
8
The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model.
Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):905-12. doi: 10.1158/1055-9965.EPI-14-1286. Epub 2015 Mar 18.
9
Mode of detection and secular time for ductal carcinoma in situ.
J Natl Cancer Inst Monogr. 2010;2010(41):142-4. doi: 10.1093/jncimonographs/lgq028.
10
Diagnosis and management of ductal carcinoma in situ (DCIS).
Evid Rep Technol Assess (Full Rep). 2009 Sep(185):1-549.

引用本文的文献

1
Multimodal genome-wide survey of progressing and non-progressing breast ductal carcinoma in-situ.
Breast Cancer Res. 2024 Dec 4;26(1):178. doi: 10.1186/s13058-024-01927-1.
2
Granulomatous mastitis masking ductal carcinoma in situ: A case report with literature review.
Biomed Rep. 2023 Dec 8;20(2):17. doi: 10.3892/br.2023.1705. eCollection 2024 Feb.
4
Stromal Changes are Associated with High P4HA2 Expression in Ductal Carcinoma in Situ of the Breast.
J Mammary Gland Biol Neoplasia. 2021 Dec;26(4):367-375. doi: 10.1007/s10911-021-09504-4. Epub 2022 Jan 25.
5
Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination.
Front Immunol. 2021 Nov 24;12:786286. doi: 10.3389/fimmu.2021.786286. eCollection 2021.
6
Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
Breast Cancer Res. 2021 Oct 30;23(1):101. doi: 10.1186/s13058-021-01479-8.
8
BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression.
NPJ Breast Cancer. 2020 Apr 24;6:12. doi: 10.1038/s41523-020-0157-z. eCollection 2020.
9
Air Pollution, Clustering of Particulate Matter Components, and Breast Cancer in the Sister Study: A U.S.-Wide Cohort.
Environ Health Perspect. 2019 Oct;127(10):107002. doi: 10.1289/EHP5131. Epub 2019 Oct 9.
10
Screening Mammography Outcomes: Risk of Breast Cancer and Mortality by Comorbidity Score and Age.
J Natl Cancer Inst. 2020 Jun 1;112(6):599-606. doi: 10.1093/jnci/djz172.

本文引用的文献

1
Obesity, mammography use and accuracy, and advanced breast cancer risk.
J Natl Cancer Inst. 2008 Dec 3;100(23):1724-33. doi: 10.1093/jnci/djn388. Epub 2008 Nov 25.
4
The association of mammographic density with ductal carcinoma in situ of the breast: the Multiethnic Cohort.
Breast Cancer Res. 2006;8(3):R30. doi: 10.1186/bcr1507. Epub 2006 Jun 23.
7
Extra-tumoral breast tissue in breast cancer patients: variations with steroid contraceptive use.
Int J Cancer. 2006 Jun 1;118(11):2827-31. doi: 10.1002/ijc.21697.
8
Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001.
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):1008-11. doi: 10.1158/1055-9965.EPI-04-0849.
10
The development of interval breast malignancies in patients with BRCA mutations.
Cancer. 2004 May 15;100(10):2079-83. doi: 10.1002/cncr.20221.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验